Cipla announced its Q3 FY26 results, highlighting a strong recovery in India with 10% YoY growth. Overall chronic mix improved to 62.3%. North America delivered $167 million in quarterly revenue. Prescription business in One Africa ranked No. 2. Emerging Markets and Europe delivered fourth consecutive quarter above $100Mn+. R&D investments increased to INR 494 Cr.
Financial Performance Overview
Cipla’s unaudited consolidated financial results for Q3 FY26 showcase positive momentum. Key highlights include:
- Income from Operations: INR 7,074 Cr
- EBITDA: INR 1,255 Cr (18%)
- PAT: INR 676 Cr (10%)
India Business Performance
The India business demonstrated robust growth, delivering a 10% YoY increase for the quarter. The chronic segment mix improved significantly, reaching 62.3%. This growth was fueled by strong performance in branded prescriptions, trade generics, and consumer health.
North America Performance
North America delivered a quarterly revenue of $167 Mn. The company anticipates upcoming launches to mitigate gRevlimid revenue decline and provide sustained long-term growth.
Other Key Market Highlights
- One Africa: Prescription business secured the No. 2 position in the market.
- Emerging Markets and Europe: Revenue exceeded $100Mn+ for the fourth consecutive quarter, achieving 7% YoY growth in USD terms.
R&D Investment
Cipla’s commitment to innovation is reflected in its R&D investments, which stood at INR 494 Cr, representing 7.0% of sales. This marks a 37.4% YoY increase, driven by heightened product filing activity and development initiatives.
Balance Sheet Strength
Cipla maintains a strong financial position with a net cash balance of INR 10,229 Cr. Debt primarily consists of lease liabilities.
Segmental Performance Details
Key aspects of the segmental performance are detailed below:
- Branded Prescription: Achieved strong double-digit growth of 10% YoY, with key therapies like Respiratory and Urology demonstrating strong market growth.
- Trade Generics: Recorded healthy growth, supported by distribution excellence and new product introductions.
Source: BSE
